Matheson I
Institutt for farmakoterapi Postboks, Blindern, Oslo.
Tidsskr Nor Laegeforen. 1996 Jun 20;116(16):1904-6.
Thousands of women with breast cancer have received high dose chemotherapy prior to the results from controlled clinical trials being known. As one of these patients the author reviews and discusses the results of the first randomised study from South Africa. High dose therapy with autologous stem cell support was compared with conventional chemotherapy in 90 young women with metastatic aggressive breast cancer. Though survival was short in both groups the disease free survival was doubled in the high dose group. A significant increase was found in response rate, duration of response and survival. Data from America show the cost effectiveness of this treatment to be comparable to that of other life-saving therapies. A comparison is made with the absolute and relative survival benefit of simvastatin treatment. A Norwegian White Paper on high dose therapy does not include advanced breast cancer in the planned trial protocols. It is argued that future health planning should give high priority to the treatment of advanced breast cancer in young women.
在对照临床试验结果知晓之前，数千名乳腺癌女性已接受了高剂量化疗。作为其中一名患者，作者回顾并讨论了南非首项随机研究的结果。在90名患有转移性侵袭性乳腺癌的年轻女性中，对自体干细胞支持的高剂量疗法与传统化疗进行了比较。尽管两组的生存期都很短，但高剂量组的无病生存期延长了一倍。在缓解率、缓解持续时间和生存期方面均发现有显著提高。来自美国的数据表明，这种治疗的成本效益与其他挽救生命的疗法相当。文中将其与辛伐他汀治疗的绝对和相对生存获益进行了比较。挪威一份关于高剂量疗法的白皮书在计划的试验方案中未将晚期乳腺癌纳入其中。有人认为，未来的健康规划应高度重视年轻女性晚期乳腺癌的治疗。
